Alkermes Plc Hits New 52-Week High of USD 42.83

Alkermes Plc has reached a significant milestone by hitting a new 52-week high of USD 42.83 on May 29, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 4,771 million. Over the past year, Alkermes has demonstrated impressive growth, with a performance increase of 74.41%, significantly outpacing the S&P 500's 28.21% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 14.00, indicating a favorable valuation relative to its earnings. Additionally, Alkermes maintains a return on equity of 19.54%, reflecting effective management and profitability. Despite a debt-to-equity ratio of -0.64, which suggests a strong balance sheet, the company does not currently offer a dividend yield. The stock's previous 52-week low was recorded at USD 25.17, highlighting the substantial upward movement in its price. This new high marks a notable point in Alkermes' ongoing performance trajectory within the competitive pharmaceutical landscape.